PROKIDNEY CORP.

ProKidney Corp. (Nasdaq: DNAC) is a clinical-stage biotherapeutics company developing cell-based therapies for chronic kidney disease. The company became a publicly traded issuer through its 2022 business combination with SCS Capital Acquisition Corp., a healthcare-focused blank-check vehicle that completed its IPO in 2021, with SCS Capital serving as sponsor. ProKidney's lead program, REACT, is an investigational autologous cell therapy designed for patients with chronic kidney disease. The company remains an active SEC reporting issuer, having filed an 8-K on May 15, 2026. For comprehensive SPAC transaction records, filing history, and sector data on ProKidney and thousands of other deals, sign up for full access at SpacDesk.